180 related articles for article (PubMed ID: 12469988)
1. Donepezil: tolerability and safety in Alzheimer's disease.
Pratt RD; Perdomo CA; Surick IW; Ieni JR
Int J Clin Pract; 2002 Nov; 56(9):710-7. PubMed ID: 12469988
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
3. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
[TBL] [Abstract][Full Text] [Related]
4. Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions.
Geldmacher DS
Expert Rev Neurother; 2004 Jan; 4(1):5-16. PubMed ID: 15853610
[TBL] [Abstract][Full Text] [Related]
5. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.
Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Takase T; Ohbayashi T
Dement Geriatr Cogn Disord; 2009; 27(3):232-9. PubMed ID: 19246907
[TBL] [Abstract][Full Text] [Related]
7. Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials.
Winblad B; Black SE; Homma A; Schwam EM; Moline M; Xu Y; Perdomo CA; Swartz J; Albert K
Curr Med Res Opin; 2009 Nov; 25(11):2577-87. PubMed ID: 19735164
[TBL] [Abstract][Full Text] [Related]
8. Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials.
Passmore AP; Bayer AJ; Steinhagen-Thiessen E
J Neurol Sci; 2005 Mar; 229-230():141-6. PubMed ID: 15760632
[TBL] [Abstract][Full Text] [Related]
9. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
10. Memantine: new preparation. Poor evaluation and uncertain benefit in Alzheimer's disease.
Prescrire Int; 2003 Dec; 12(68):203-5. PubMed ID: 14986682
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
Burns A; Gauthier S; Perdomo C
Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
Sakka P; Tsolaki M; Hort J; Hager K; Soininen H; López Pousa S; Li C; Schwam E
Curr Med Res Opin; 2007 Dec; 23(12):3153-65. PubMed ID: 17988434
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials.
Sadowsky CH; Farlow MR; Meng X; Olin JT
Int J Clin Pract; 2010 Jan; 64(2):188-93. PubMed ID: 20089009
[TBL] [Abstract][Full Text] [Related]
14. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
[TBL] [Abstract][Full Text] [Related]
15. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
[TBL] [Abstract][Full Text] [Related]
16. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.
Rogers SL
Dement Geriatr Cogn Disord; 1998; 9 Suppl 3():29-42. PubMed ID: 9853200
[TBL] [Abstract][Full Text] [Related]
17. Update on Alzheimer drugs (donepezil).
Smith Doody R
Neurologist; 2003 Sep; 9(5):225-9. PubMed ID: 12971832
[TBL] [Abstract][Full Text] [Related]
18. Donepezil in the treatment of mild to moderate Alzheimer's disease: report of a Belgian multicenter study.
Santens P; Ventura M
Acta Neurol Belg; 2003 Sep; 103(3):159-63. PubMed ID: 14626696
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
[TBL] [Abstract][Full Text] [Related]
20. Anticholinesterases in Alzheimer's disease: a modest effect on moderately severe disease.
Prescrire Int; 2003 Dec; 12(68):230-1. PubMed ID: 14986699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
